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Angiotensin II-induced growth of vascular smooth muscle cells Besides its key regulatory role in blood pressure con-
requires an Src-dependent activation of the epidermal growth trol by vascular constriction, angiotensin II (Ang II) also
factor receptor. induces cellular hypertrophy and proliferation of vascu-Background. Angiotensin II (Ang II) is a potent stimulus of
lar smooth muscle cells (VSMCs) [1]. Therefore, Ang IIvascular smooth muscle cell (VSMC) growth. Activation of extra-
cellular signal-regulated kinase (ERK), the archetypal mitogen- is considered to contribute to the development of various
activated protein (MAP) kinase, and phosphatidylinositol 3 (PI3) cardiovascular diseases accompanied by VSMC growth
kinase are critical steps in Ang II-induced mitogenic signaling. such as hypertension, atherosclerosis, and restenosis fol-However, the mechanism involved in the activation of these ki-
lowing balloon angioplasty [2–4]. Thus, it is importantnases upon binding of Ang II to its receptor is poorly understood.
Methods. In the present study, we examined the role of the to understand the underlying intracellular signaling
epidermal growth factor receptor (EGFR) in Ang II signaling in mechanisms involved in the Ang II-induced growth re-
VSMCs employing immunoprecipitation, Western blot analysis, sponse of VSMCs.kinase immunocomplex assay, and [3H]-thymidine incorporation.
Major intracellular signaling pathways involved in theResults. A time-dependent tyrosine phosphorylation of the
regulation of cell growth and division in response toEGFR in response to Ang II was observed that was mediated
by the Ang II type 1 receptor. This transactivation of the EGFR growth factors, by stimulation of transmembrane recep-
was blocked in the presence of PP1, an inhibitor of the intracel- tors with intrinsic protein tyrosine kinase activity or
lular Src-like tyrosine kinases. The tyrphostin AG 1478, a selec-
G-protein–coupled receptors (GPCRs), are the mitogen-tive EGFR antagonist, inhibited both Ang II- and EGF-induced
activated protein (MAP) kinase cascades [5, 6]. Extracel-tyrosine phosphorylation of the EGFR. Furthermore, Ang II
induced the binding of the adaptor protein Shc to the EGFR, lular signal-regulated kinase (ERK), the best described
leading to phosphorylation of Shc. In addition, the same nano- mammalian MAP kinase, mediates growth of VSMCs in
molar concentrations of AG 1478 that were effective in EGF
response to Ang II [5–7]. In addition, phosphatidylinosi-signaling blocked the Ang II-induced activation of ERK and
tol 3 (PI3) kinase has recently been implicated in Ang II-PI3 kinase in a dose-dependent manner. Proliferation of VSMCs,
detected by measurements of DNA synthesis, following stimu- induced growth of VSMCs [8].
lation with Ang II was potently inhibited in the presence of Although the intracellular signaling molecules in-
AG 1478 or PP1.
volved in ERK and PI3 kinase activation following stim-Conclusion. Our data suggest that EGFR serves as a role in
ulation of a receptor tyrosine kinase (RTK) are wellmitogenic signaling following stimulation with Ang I through
a ligand-independent and Src-dependent transactivation of the defined, little is known about the mechanisms of ERK
EGFR. Furthermore, we demonstrate this transactivation as a and PI3-kinase stimulation following binding of Ang II
pivotal step in Ang II-induced activation of MAP kinase and
to its seven transmembrane, heterotrimeric GPCRs. Re-PI3 kinase, as well as growth of VSMCs.
cently, intracellular transactivation of the epidermal growth
factor receptor (EGFR) has been suggested to mediate
ERK activation and cellular proliferation following stim-
1 See Editorial by Harris, p. 898 ulation with agonists of GPCR, such as endothelin-1,
thrombin, or lysophosphatidic acid in fibroblasts [9]. InKey words: transactivation, cell proliferation, mitogen-activated pro-
tein kinase, hypertension, cardiovascular disease, atherosclerosis. correlation, we demonstrate in the present study signifi-
cant evidence for an Src-dependent intracellular trans-
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METHODS when blotting for the EGFR. Protein was transferred to
nitrocellulose (pore size, 0.45 mm; Schleicher andMaterials
Schuell, Keene, NH, USA) and probed with polyclonal
The enhanced chemiluminescent (ECL) system was ob- antibodies against the C-terminal peptide of p42 ERK
tained from Amersham Corp. (Braunschweig, Germany), (generous gift from M.J. Dunn [11]), Shc (Transduction
and Eagle’s minimum essential medium (MEM) cell cul- Laboratories Inc.), EGFR (Santa Cruz Biotech Inc.),
ture media were from GIBCO BRL (Grand Island, NY, Akt, in position 473 phosphorylated Akt (both from
USA). AG 1478 and AG 1296 were purchased from Cal- New England Biolabs), or with a monoclonal antibody
biochem (La Jolla, CA, USA), and [3H]-thymidine was recognizing phosphotyrosine (PY20). The primary anti-
from New England Nuclear (Boston, MA, USA). Protein bodies (diluted 1:1000) were detected using horseradish
A-sepharose was obtained from Pharmacia Biotech, Inc. peroxidase-conjugated protein A visualized by the Am-
(Freiburg, Germany). Rabbit polyclonal anti-EGFR an- ersham ECL system after intensive washing of the mem-
tibody, anti-ERK antibody, anti–platelet-derived growth branes. The representative results are shown; the experi-
factor (PDGF) b receptor antibody, anti-insulin-like ments were reproduced at least twice.
growth factor-1 (IGF-1) receptor b-subunit antibody,
and mouse monoclonal antiphosphotyrosine antibody Immunoprecipitation
were purchased from Santa Cruz Biotech Inc. (Santa Confluent VSMCs were washed with ice-cold PBS and
Cruz, CA, USA). Rabbit polyclonal anti-Shc antibody lyzed in Triton X-100 lysis buffer (as described pre-
was obtained from Transduction Laboratories, Inc. (Lex- viously in this article) for five minutes at 48C. Insoluble
ington, KY, USA). Rabbit polyclonal anti-phospho-Elk1 material was removed by centrifugation at 10,000 3 g
antibody, anti-phospho-Akt antibody, anti-Akt anti- for 15 minutes at 48C. Cell lysates (500 mg protein) were
body, and Elk1-glutathione-S-transferase (GST) fusion incubated for two hours with polyclonal anti-EGFR anti-
protein were purchased from New England Biolabs (Bev- body or monoclonal PY20 antibody. Immunocomplexes
erly, MA, USA). Recombinant Ang II, EGF, PDGF- were adsorbed to protein A- or protein G-sepharose
BB, and all other reagents were obtained from Sigma and washed three times with lysis buffer. Proteins were
Chemicals (St. Louis, MO, USA). resolubilized by the addition of an equal volume of 2 3
Laemmli buffer and were detected by Western blot anal-Cell culture
ysis, as described previously in this article.
Rat VSMCs were isolated as described previously [10].
Nonradioactive ERK activity assayBriefly, the thoracic aortas of male Sprague-Dawley rats
were isolated. Following a short incubation in MEM Five hundred micrograms of soluble cell lysates (as
containing collagenase, elastase, and trypsin inhibitor, described previously in this article) were incubated for
the adventitia was stripped. Thereafter, the aortas were 90 minutes with 10 mL of polyclonal antibody recognizing
minced and incubated a second time in Eagle’s MEM p42 ERK (Santa Cruz Biotech Inc.). Immunocomplexes
containing the same supplements as used before until a were adsorbed to protein A-sepharose, washed twice
single-cell suspension was achieved. VSMCs were cul- with lysis buffer and twice with kinase buffer (10 mmol/L
tured in Eagle’s MEM supplemented with 10% fetal bo- MgCl2, 20 mmol/L HEPES, pH 7.4, containing 200 mmol/L
vine serum (FBS), 100 U/mL penicillin, and 100 mg/mL Na-orthovanadate), and resuspended in 60 mL of kinase
streptomycin. VSMCs were serum starved for 20 hours buffer containing 50 mmol/L adenosine 59-triphosphate
in serum-free Eagle’s MEM prior to stimulation with (ATP) and 2 mg GST-Elk1 fusion protein. The reaction
various agonists. Experiments were conducted with cells was initiated by incubation at 308C for 45 minutes. To
between the third and tenth passages. terminate the reaction, 20 mL of 4 3 Laemmli buffer
were added, and samples were subjected to a 10% SDS-
Western blot analysis PAGE. Thereafter, proteins were analyzed by Western
Confluent VSMCs were washed with ice-cold phos- blot analysis, as described previously in this article, em-
phate-buffered saline (PBS) and lyzed in 400 mL Triton ploying a polyclonal anti–phospho-Elk1 antiserum rec-
X-100 lysis buffer at 48C. After five minutes, cells were ognizing only the in position 383 phosphorylated form
scraped with a cell lifter and were centrifuged at 48C for of Elk1.
15 minutes at 10,000 3 g. The soluble cell lysates were
Src kinase assaymixed 1:4 with 5 3 Laemmli buffer and heated for five
minutes at 958C. Eighty micrograms of soluble cell ly- p60c-Src immunoprecipitates were washed three times in
sates were loaded per lane and separated by sodium lysis buffer and twice in kinase reaction buffer (20 mmol/L
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS- PIPES, pH 7.0, and 10 mmol/L MnCl2). The precipitates
PAGE) using 10% acrylamide for resolving gels when were then suspended in the kinase reaction buffer con-
taining 50 mmol/L ATP with or without 5 mg of acid-blotting for ERK or 7% acrylamide for resolving gels
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Fig. 1. Angiotensin II (Ang II) induces tyrosine phosphorylation of
the epidermal growth factor receptor (EGFR). (A) Quiescent vascular
smooth muscle cells (VSMCs) were stimulated with Ang II or EGF for
five minutes. (Upper panel) Cellular protein was immunoprecipitated
employing polyclonal anti-EGFR antiserum followed by a Western
blot analysis using monoclonal antiphosphotyrosine antibody (PY). The
band of the EGFR, as indicated by the arrow, correlated to the expected
size of 170 kD. (Lower panel) Equal loading was confirmed by reprobing
immunoblots with polyclonal anti-EGFR antiserum. (B) VSMCs were
stimulated with Ang II (100 nmol/L) or EGF (1 ng/mL) for the indicated
periods of time and were analyzed as described in (A). (C) VSMCs
were stimulated with Ang II or EGF for five minutes. Cellular lysates
were immunoprecipitated with monoclonal PY antibody. Immunopre-
cipitates were analyzed by SDS-PAGE and immunoblotted with poly-
clonal anti-EGFR antiserum.
denatured rabbit muscle enolase. The kinase reaction RESULTS
was started by the addition of 10 mCi [g-32P]ATP at Ang II-induced EGFR transactivation depends on
308C and terminated after 10 minutes by the addition of c-Src activity
Laemmli buffer. Reactions with enolase contained an
To analyze the role of the EGFR in Ang II-inducedadditional 30 mmol/L PIPES, pH 7.0, to neutralize the
growth of VSMCs, we initially evaluated the extent ofacid from the pretreatment of enolase.
tyrosine phosphorylation of the EGFR following stimu-
lation with Ang II. Tyrosine phosphorylation of theDNA synthesis
EGFR was detected by EGFR immunoprecipitates that[3H]-thymidine incorporation into DNA was assessed
were blotted with a monoclonal antiphosphotyrosine an-as previously described [12]. Briefly, subconfluent
tibody. As shown in Figure 1A, Ang II induced a rapidVSMCs were placed into serum-free medium consisting
activation of the EGFR, as detected by the tyrosineof a mixture of MEM and Ham’s medium (1:1, vol/vol)
autophosphorylation of the EGFR. The band of thefor 24 hours. Thereafter, VSMCs were stimulated with
EGFR was running according to its expected size of 170Ang II or EGF in the presence or absence of the tyrphos-
kD. In comparison with EGF-mediated stimulation oftin AG 1478 for 24 hours prior to the addition of [3H]-
the EGFR, Ang II-induced EGFR phosphorylation wasthymidine (3 mCi/mL) for four hours. Acid-insoluble
less pronounced. However, Ang II (100 nmol/L) was as[3H]-thymidine was extracted in 0.5 mol/L NaOH and
potent as 1 ng/mL EGF (Fig. 1 A, C). Equal loading wasquantitated by liquid scintillation counting.
confirmed by reprobing immunoblots with an polyclonal
Statistics anti-EGFR antiserum (Fig. 1A, lower panel). Figure 1B
shows a typical time course of Ang II-stimulated trans-Values are expressed as means 6 SEM. Statistical
activation of the EGFR, demonstrating EGFR tyrosineanalysis were performed employing the Student’s t-test.
P , 0.05 was considered statistically significant. phosphorylation within two minutes and maximally after
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Fig. 2. Ang II induces autophosphorylation of the EGFR via the AT1 receptor. (A) Quiescent VSMCs were stimulated with Ang II (100 nmol/L)
or EGF (10 ng/mL) for five minutes. Prior to stimulation, cells were incubated for 20 minutes with the AT1 receptor blocker Candesartan (10
nmol/L), the EGFR-specific tyrphostin AG 1478 or the PDGF receptor-specific tyrphostin AG 1296 (10 mmol/L) as indicated. Cellular proteins
were analyzed as described in Figure 1A. (B) VSMCs were stimulated with Ang II (100 nmol/L) or PDGF-BB (20 ng/mL) for the indicated periods
of time. (Upper panel) Cellular protein was immunoprecipitated employing anti-PDGF b receptor (PDGFR) antiserum followed by a Western
blot analysis using PY antibody. (Lower panel) Equal loading was confirmed by reprobing immunoblots with polyclonal anti-PDGFR antiserum.
(C) VSMCs were stimulated with Ang II (100 nmol/L) or IGF-1 (50 ng/mL) for the indicated periods of time. (Upper panel) Cellular protein was
immunoprecipitated employing anti–IGF-1 receptor b subunit (IGF-1R) antiserum followed by a Western blot analysis using PY antibody. (Lower
panel) Loading of the gel was controlled by reprobing immunoblots with polyclonal anti–IGF-1R antiserum.
five minutes following stimulation with Ang II (Fig. 1B). ies suggested that the PDGF receptor [14], as well as
tyrosine phosphorylation of the insulin receptor sub-Ang II-induced tyrosine phosphorylation of the EGFR
was confirmed by immunoprecipitation employing an strate 1 [15], plays a role in Ang II-induced signaling in
VSMCs. However, in the present study, we were notantiphosphotyrosine antibody followed by a Western
blot analysis with an anti-EGFR antiserum (Fig. 1C). able to detect an activation of either the PDGF receptor
(Fig. 2B) or the IGF-1 receptor (Fig. 2C) in response toSpecific inhibition of EGFR activity by the selective
tyrphostin AG 1478 [9, 13] dose dependently prevented cellular stimulation with Ang II. In addition, the tyrphos-
tin AG 1296 that selectively inhibits activity of the PDGF(at concentrations from 3 to 300 nmol/L) the EGF-stimu-
lated tyrosine autophosphorylation of the EGFR (Fig. receptor, in a concentration that potently inhibited
PDGF-induced ERK-activation (Fig. 6A), did not affect2A). We also demonstrate that the same nanomolar con-
centrations of AG 1478 inhibit the Ang II-induced EGFR activation (Fig. 2A).
To evaluate the role of the Src kinase family, cyto-EGFR tyrosine phosphorylation (Fig. 2A). Furthermore,
Candesartan, a selective AT1 receptor antagonist, sig- plasmic tyrosine kinases, we employed the specific Src
inhibitor PP1 [16]. We detected a significant activationnificantly reduced the Ang II-induced activation of the
EGFR (Fig. 2A). Therefore, Ang II-mediated activation of c-Src following cellular stimulation with Ang II (Fig.
3A). The degree of Ang II-induced c-Src stimulation wasis mediated by the AT1 receptor rather than by unspe-
cific binding of Ang II to the EGFR. Equal loading comparable to previously published data [28]. In the
presence of PP1, a dose-dependent inhibition of the Angwas confirmed by reprobing immunoblots with an anti-
EGFR antiserum (Fig. 2A, lower panel). Previous stud- II-induced Src (Fig. 3A) as well as EGFR activity (Fig.
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Fig. 3. Ang II-induced phosphorylation of the EGFR is blocked by Src inhibition. (A) Quiescent VSMCs were stimulated with Ang II (100
nmol/L) for two minutes. Prior to stimulation, cells were incubated for two minutes with the Src family-specific inhibitor PP1 as indicated. Cellular
lysates were analyzed by pp60c-src autophosphorylation assay. (B) VSMCs were stimulated with Ang II (100 nmol/L) or EGF (10 ng/mL) for five
minutes. Prior to stimulation, cells were incubated for two minutes with the Src family-specific inhibitor PP1 as indicated. (Upper panel) Cellular
protein was immunoprecipitated employing anti-EGFR antiserum followed by a Western blot analysis using antiphosphotyrosine antibody (PY).
(Lower panel) Equal loading was confirmed by reprobing immunoblots with polyclonal anti-EGFR antiserum.
3B, upper panel) was observed. PP1 in high concentra-
tions did not affect the EGF-induced activation of the
EGFR (Fig. 3B, upper panel). Equal loading was con-
firmed by reprobing immunoblots with an polyclonal
anti-EGFR antiserum (Fig. 3B, lower panel).
Ang II induces association of Shc to the EGFR and
Shc phosphorylation
In the present study, we evaluated whether Ang II- Fig. 4. Ang II induces Shc association with the EGFR. Quiescent
VSMCs were stimulated with Ang II (100 nmol/L) or EGF (10 ng/mL)induced activation of the EGFR initiates well-defined
for five minutes. Prior to stimulation, cells were incubated for 20 minutessignaling events like binding of the adaptor protein Shc with the EGFR-specific tyrphostin AG 1478 (300 nmol/L) as indicated.
to the EGFR. At the EGFR, Shc is known to get tyrosine Cellular protein was immunoprecipitated employing polyclonal anti-
Shc antiserum followed by a Western blot analysis using polyclonalphosphorylated [17, 18]. Therefore, Shc immunoprecipi-
anti-EGFR antiserum.tates were immunoblotted with an anti-EGFR polyclonal
antibody. The results of these experiments are shown in
Figure 4 and demonstrate that Ang II is indeed able to
induce an association of the EGFR with Shc. This com- more, Shc phosphorylation following stimulation with
Ang II was confirmed by a Western blot analysis ofplex formation was dependent on EGFR kinase activity,
since we show AG 1478 to inhibit binding of Shc to the phosphotyrosine immunoprecipitates employing an anti-
Shc antibody. However, because of a lesser sensitivityEGFR (Fig. 4). As expected, reprobing of the cellulose
membrane with an antiphosphotyrosine antibody dem- of this method, only the tyrosine phosphorylation of p52
Shc was detectable (Fig. 5B).onstrated that the EGFR coprecipitating with Shc is the
tyrosine-phosphorylated form of the EGFR (data not
Ang II activates ERK and PI3 kinase throughshown). In addition, cellular stimulation of VSMCs with
the EGFRAng II induced a tyrosine phosphorylation of the p52 and
p66 isoforms of Shc, as detected by immunoprecipitation Epidermal growth factor and Ang II induced a rapid
stimulation of ERK (Fig. 6A), as detected by the ERKwith an anti-Shc antibody followed by immunoblotting
with an antiphosphotyrosine antibody (Fig. 5A). As ex- immunocomplex assay. ERK activity was assayed by the
ability of immunoprecipitated ERK to phosphorylate inpected, EGF in a concentration of 10 ng/mL induced a
more potent phosphorylation of Shc, including a weak vitro a GST fusion protein of the transcription factor
Elk1. In the presence of the tyrphostin AG 1478 [9, 13],tyrosine phosphorylation of the p46 isoform. In the pres-
ence of the EGFR-specific tyrphostin AG 1478, Shc Ang II-induced ERK activation was potently inhibited
(Fig. 6A), suggesting that transactivation of the EGFRphosphorylation was potently inhibited (Fig. 5A), dem-
onstrating the essential role of EGFR kinase activity in is crucial for Ang II-induced ERK activation. In contrast,
selective inhibition of the PDGF receptor activity by theAng II-induced signaling via the adaptor protein Shc.
Equal loading was demonstrated by reprobing immu- tyrphostin AG 1296 [13], which was shown to inhibit
PDGF-induced ERK activation (Fig. 6A), did not affectnoblots with an anti-Shc antiserum (Fig. 5A). Further-
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Fig. 5. Ang II induces Shc tyrosine phosphorylation. (A) Quiescent VSMCs were stimulated with Ang II (100 nmol/L) or EGF (10 ng/mL) for
five minutes. Prior to stimulation, cells were incubated for 20 minutes with the EGFR-specific tyrphostin AG 1478 (300 nmol/L) as indicated.
(Left panel) Cellular protein was immunoprecipitated employing anti-Shc antiserum followed by a Western blot analysis using antiphosphotyrosine
(PY) antibody. (Right panel) Equal loading was confirmed by reprobing immunoblots with anti-Shc antiserum. The three expected isoforms of
Shc are indicated. (B) VSMCs were stimulated with Ang II or EGF for five minutes. Cellular protein was immunoprecipitated employing PY
antibody followed by a Western blot analysis using anti-Shc antiserum.
Fig. 6. Ang II induces ERK activation via the
EGFR. (A) Quiescent VSMCs were stimulated
with Ang II (100 nmol/L), EGF (1 ng/mL), or
PDGF (200 ng/mL) for the indicated periods
of time. Prior to stimulation, cells were incu-
bated for 20 minutes with the EGFR-specific
tyrphostin AG 1478 (30 nmol/L), the PDGF re-
ceptor-specific tyrphostin AG 1296 (10 mmol/L),
or Candesartan (1 nmol/L) as indicated. ERK
activity is assayed by the ability of immuno-
precipitated ERK to phosphorylate a GST-
fusion protein of the transcription factor Elk1.
The kinase reaction was followed by Western
blot analysis (10% SDS-PAGE) with a poly-
clonal antiphospho-Elk1 antiserum recogniz-
ing only the in position 383, site of phosphory-
lation by ERK, phosphorylated form of Elk1.
(B) VSMCs were stimulated with Ang II (100
nmol/L) or EGF (10 ng/mL) for five minutes.
Prior to stimulation, cells were incubated for
20 minutes with different concentrations of
the EGFR-specific tyrphostin AG 1478 as in-
dicated. (Upper panel) Western blot analysis
detecting both p42 ERK in whole cellular ly-
sates. Activation of ERK is identifiable by
an increase of phosphorylated protein forms,
detected by bands with delayed mobility (indi-
cated by stars). (Lower panel) ERK activity is
assayed by the ability of immunoprecipitated
ERK to phosphorylate the GST fusion protein
of the transcription factor Elk1, as described
previously in this article.
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tein forms (Fig. 8). Akt is a known substrate of an acti-
vated PI3-kinase signaling [20]. The same concentrations
of AG 1478 that were effective in blocking ERK activa-
tion in the presence of Ang II also prevented the Ang II-
induced stimulation of PI3 kinase (Fig. 8). In addition,
similar concentrations of AG 1478 inhibited EGF-induced
phosphorylation of Akt (Fig. 8). Equal loading was con-
firmed by reprobing immunoblots with an polyclonal
anti-Akt antiserum (Fig. 8, lower panel).
EGFR transactivation mediates Ang II-induced
DNA synthesis
To evaluate the functional relevance of EGFR activa-
tion following stimulation with Ang II, we measured
Ang II-induced DNA synthesis, as detected by [3H]-
thymidine incorporation, in the presence and absence of
the EGFR tyrphostin or the Src inhibitor. Incubation
with AG 1478 or PP1 effectively reduced the EGF-medi-
ated increase in DNA synthesis (P , 0.001 and P , 0.05,
respectively; Fig. 9). Ang II stimulated the DNA synthesis
to a lesser extent than EGF. However, inhibition of the
EGFR kinase activity by AG 1478 (P , 0.05) or Src
Fig. 7. Ang II-induced ERK activation in fibroblasts devoid of endoge- activity by PP1 (P , 0.05) completely blocked the increase
nous EGFR. (A) Cellular lysates of 2.2 and HER cells were immunopre- in DNA synthesis following Ang II stimulation (Fig. 9).cipitated employing polyclonal anti-EGFR antiserum followed by a
Western blot analysis using polyclonal anti-EGFR antiserum. (B) Qui-
escent HER and 2.2 cells were stimulated with Ang II, EGF, or PDGF
DISCUSSIONfor 10 minutes. ERK activity was assayed by an immunocomplex assay
as described previously in this article. Angiotensin II has been suggested to contribute to
the development of various cardiovascular diseases ac-
companied by VSMC growth such as hypertension, ath-
ERK activity following Ang II stimulation (Fig. 6A). As erosclerosis, and restenosis following balloon angio-
expected, Candesartan inhibited Ang II, but not EGF- plasty [2–4]. Pharmacological inhibition of the ERK
stimulated ERK activity. Both EGF- and Ang II-induced cascade by the MEK inhibitor PD 98059 demonstrated
ERK activation were inhibited in a similar range of nano- that the ERK signaling pathway is necessary for the
molar concentrations of AG 1478 (Fig. 6B), as deter- induction of VSMC growth [7]. In addition, PI3 kinase
mined by Western blot analysis detecting p42 ERK (up- has recently been implicated in Ang II-induced growth
per panel) and by ERK immunocomplex assay (lower promoting signaling in VSMCs [8]. Little is known about
panel). In correlation to the data presented in Figures the mechanisms of ERK or PI3-kinase stimulation upon
1 and 2, EGF (10 ng/mL) was a more potent stimulus binding of Ang II to its seven transmembrane, hetero-
of ERK activity than Ang II (100 nmol/L). To evaluate trimeric GPCR. Recently, intracellular transactivation
the role of the EGFR in Ang II-induced ERK activation of the EGFR has been suggested to mediate ERK activa-
in a cellular system without an EGFR inhibitor, we em- tion and cellular proliferation following stimulation with
ployed established NIH3T3 cells devoid of endogenous endothelin-1, thrombin, and lysophosphatidic acid in fi-
EGFR (2.2 cells) that got the EGFR reintroduced by broblasts [9]. Moreover, Ang II-induced activation of
stable transfection (HER cells) [19]. The data presented ERK was shown to be dependent on tyrosine kinase
in Figure 7A reconfirm the levels of EGFR expression activity [21].
in these cells. In cells without an EGFR (2.2 cells), nei- The present study demonstrates an activation of the
ther EGF nor Ang II induced a significant ERK activa- EGFR in response to stimulation with Ang II in VSMCs,
tion (Fig. 7B). In contrast, PDGF was a potent stimulus as detected by EGFR tyrosine phosphorylation measure-
of ERK activation. However, in NIH3T3 cells that got ments employing immunoprecipitation of the EGFR fol-
the EGFR reintroduced, both EGF and Ang II were lowed by immunoblotting with an antiphosphotyrosine
capable of stimulating ERK (Fig. 7B). antibody. These data were confirmed by phosphotyro-
As expected, Ang II induced an activation of PI3 ki- sine immunoprecipitates that were blotted with an anti-
nase, assayed by the phosphorylation of Akt employing EGFR antibody. Our data present significant evidence
for a rapid tyrosine phosphorylation of the EGFR fol-an antiserum that detects only the phosphorylated pro-
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Fig. 8. Dose-dependent inhibition of Ang II-
induced Akt phosphorylation by AG 1478.
Quiescent VSMCs were stimulated with Ang
II (100 nmol/L) or EGF (10 ng/mL) for five
minutes. Prior to stimulation, cells were incu-
bated for 20 minutes with different concentra-
tions of the EGFR-specific tyrphostin AG
1478. (Upper panel) Western blot analysis of
whole cellular lysates detecting in position 473
phosphorylated Akt employing a polyclonal
antiserum. Activation of PI3 kinase is identi-
fiable by an increase of phosphorylated Akt
protein forms. (Lower panel) Equal loading
was confirmed by reprobing immunoblots
with polyclonal anti-Akt antiserum.
Fig. 9. Ang II-induced DNA synthesis is me-
diated by transactivation of the EGFR. Quies-
cent VSMCs were stimulated with Ang II (100
nmol/L) or EGF (10 ng/mL) in the presence
or absence of AG 1478 (300 nmol/L) or PP1
(10 mmol/L).
lowing cellular stimulation with Ang II via activation of vation of the EGFR in response to stimulation of a
GPCR by bradykinin is calcium dependent [22]. Further-the AT1 receptor. Candesartan, a selective antagonist of
the AT1 receptor, blocked the Ang II-induced activation more, Ang II-induced activation of ERK has been dem-
onstrated to be calcium-dependent [21, 23]. Based onof EGFR as well as ERK activation, thus excluding a
direct effect of Ang II on the EGFR by unspecific bind- these findings, it has recently been demonstrated that the
Ang II-induced transactivation of the EGFR is calciuming. The rapid kinetics of EGFR activation most proba-
bly exclude the involvement of EGFR ligands in this dependent, but independent of an activation of protein
kinase C in VSMCs [24]. Studies in cardiac fibroblastsreceptor-mediated signal activation process. In compari-
son with the Ang II-mediated stimulation, EGF-induced [25] and liver epithelial cells [26] also focused on the
role of intracellular calcium and protein kinase C in thereceptor autophosphorylation was more pronounced.
However, EGFR activation correlated closely with the Ang II-induced activation of the EGFR. The present
study demonstrates, to our knowledge for the first time,Ang II- and EGF-induced extent of ERK and PI3-kinase
activity as well as DNA synthesis. Full phosphorylation that the Ang II-induced transactivation of the EGFR
depends on the activity of cytoplasmatic Src-like tyrosineon tyrosine of the EGFR appeared to be dependent on
receptor autophosphorylation, since it was potently inhib- kinases, since a pharmacological inhibition of the Src
kinase family with PP1 effectively blocked the Ang II-ited by the EGFR-selective tyrphostin AG 1478 [13]. In
neuroneal cells, it has been shown that a similar transacti- induced Src activity as well as tyrosine phosphorylation
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2. Daemen MJ, Lombardi DM, Bosman FT, Schwarts SM: Angioten-of the EGFR. Interestingly, c-Src kinase has already
sin II induces smooth muscle cell proliferation in the normal andbeen implicated in Ang II-induced signaling in VSMCs injured rat arterial wall. Circ Res 68:450–456, 1991
[24, 27, 28]. Recently, Src has also been implicated in 3. Powell JS, Clozel JP, Mu¨ller RK, Kuhn H, Hefti F, Hosang M,
Baumgartner HR: Inhibitors of angiotensin-converting enzymeEGFR transactivation following stimulation of COS-7
prevent myointimal proliferation after vascular injury. Sciencecells with lysophosphatic acid (LPA) [29]. However, in
245:186–188, 1989
comparison to the obvious effect in VSMCs, PP1 induced 4. Gibbons GH, Dzau VJ: Angiotensin converting enzyme inhibition
and vascular hypertrophy in hypertension. Cardiovasc Drugs Theronly a moderate decrease in the Ang II-induced EGFR
4:237–242, 1990transactivation in COS-7 cells, suggesting cell line-spe-
5. Seger R, Krebs EG: The MAPK signaling cascade. FASEB J
cific differences [29]. In VSMCs, active c-Src has been 9:726–735, 1995
shown to associate with the EGFR [24] and PYK2 [30], 6. Bokemeyer D, Sorokin A, Dunn MJ: Multiple intracellular MAP
kinase signaling cascades. Kidney Int 49:1187–1198, 1996a calcium-sensitive tyrosine kinase, in response to stimu-
7. Servant MJ, Giasson E, Meoche S: Inhibition of growth factor-lation with Ang II. induced protein synthesis by a selective MEK inhibitor in aortic
The adaptor protein Shc is shown to bind by its SH2 smooth muscle cells. J Biol Chem 271:16047–16052, 1996
8. Saward I, Zahradka P: Angiotensin II activates phosphatidylino-(src homology 2) domain to tyrosine phosphorylation
sitol 3-kinase in vascular smooth muscle cells. Circ Res 81:249–257,sites of the EGFR [17, 18]. Thereafter, Shc gets tyrosine
1997
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